Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Correction: ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors.

Guerrero-Zotano AL, Stricker TP, Formisano L, Hutchinson KE, Stover DG, Lee KM, Schwarz LJ, Giltnane JM, Estrada MV, Jansen VM, Servetto A, Gavilá J, Perez-Fidalgo JA, Lluch A, Llombart-Cussac A, Bayar MA, Michiels S, André F, Arnedos M, Guillem V, Ruiz-Simon A, Arteaga CL.

Clin Cancer Res. 2019 Feb 15;25(4):1431. doi: 10.1158/1078-0432.CCR-18-4270. No abstract available.

PMID:
30770490
2.

Correction: Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer.

Hanker AB, Estrada MV, Bianchini G, Moore PD, Zhao J, Cheng F, Koch JP, Gianni L, Tyson DR, Sánchez V, Rexer BN, Sanders ME, Zhao Z, Stricker TP, Arteaga CL.

Cancer Res. 2019 Feb 15;79(4):873. doi: 10.1158/0008-5472.CAN-18-4085. No abstract available.

PMID:
30770368
3.

ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors.

Guerrero-Zotano AL, Stricker TP, Formisano L, Hutchinson KE, Stover DG, Lee KM, Schwarz LJ, Giltnane JM, Estrada MV, Jansen VM, Servetto A, Gavilá J, Perez-Fidalgo JA, Lluch A, Llombart-Cussac A, Bayar MA, Michiels S, André F, Arnedos M, Guillem V, Ruiz-Simon A, Arteaga CL.

Clin Cancer Res. 2018 Jun 1;24(11):2517-2529. doi: 10.1158/1078-0432.CCR-17-2904. Epub 2018 Mar 26. Erratum in: Clin Cancer Res. 2019 Feb 15;25(4):1431.

4.

Alternative splicing of ALCAM enables tunable regulation of cell-cell adhesion through differential proteolysis.

Hebron KE, Li EY, Arnold Egloff SA, von Lersner AK, Taylor C, Houkes J, Flaherty DK, Eskaros A, Stricker TP, Zijlstra A.

Sci Rep. 2018 Feb 16;8(1):3208. doi: 10.1038/s41598-018-21467-x.

5.

Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.

Strickland SA, Shaver AC, Byrne M, Daber RD, Ferrell PB, Head DR, Mohan SR, Mosse CA, Moyo TK, Stricker TP, Vnencak-Jones C, Savona MR, Seegmiller AC.

Leuk Res. 2018 Feb;65:67-73. doi: 10.1016/j.leukres.2017.12.012. Epub 2018 Jan 2.

6.

Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance.

Giltnane JM, Hutchinson KE, Stricker TP, Formisano L, Young CD, Estrada MV, Nixon MJ, Du L, Sanchez V, Ericsson PG, Kuba MG, Sanders ME, Mu XJ, Van Allen EM, Wagle N, Mayer IA, Abramson V, Gόmez H, Rizzo M, Toy W, Chandarlapaty S, Mayer EL, Christiansen J, Murphy D, Fitzgerald K, Wang K, Ross JS, Miller VA, Stephens PJ, Yelensky R, Garraway L, Shyr Y, Meszoely I, Balko JM, Arteaga CL.

Sci Transl Med. 2017 Aug 9;9(402). pii: eaai7993. doi: 10.1126/scitranslmed.aai7993. Erratum in: Sci Transl Med. 2019 Feb 13;11(479):.

7.

Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer.

Hanker AB, Estrada MV, Bianchini G, Moore PD, Zhao J, Cheng F, Koch JP, Gianni L, Tyson DR, Sánchez V, Rexer BN, Sanders ME, Zhao Z, Stricker TP, Arteaga CL.

Cancer Res. 2017 Jun 15;77(12):3280-3292. doi: 10.1158/0008-5472.CAN-16-2808. Epub 2017 Apr 10. Erratum in: Cancer Res. 2019 Feb 15;79(4):873.

8.

Robust stratification of breast cancer subtypes using differential patterns of transcript isoform expression.

Stricker TP, Brown CD, Bandlamudi C, McNerney M, Kittler R, Montoya V, Peterson A, Grossman R, White KP.

PLoS Genet. 2017 Mar 6;13(3):e1006589. doi: 10.1371/journal.pgen.1006589. eCollection 2017 Mar.

9.

Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies.

Shaver TM, Lehmann BD, Beeler JS, Li CI, Li Z, Jin H, Stricker TP, Shyr Y, Pietenpol JA.

Cancer Res. 2016 Aug 15;76(16):4850-60. doi: 10.1158/0008-5472.CAN-16-0058. Epub 2016 May 26.

10.

Aberrant activation of NF-κB signaling in mammary epithelium leads to abnormal growth and ductal carcinoma in situ.

Barham W, Chen L, Tikhomirov O, Onishko H, Gleaves L, Stricker TP, Blackwell TS, Yull FE.

BMC Cancer. 2015 Sep 30;15:647. doi: 10.1186/s12885-015-1652-8.

11.

Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes.

Keck MK, Zuo Z, Khattri A, Stricker TP, Brown CD, Imanguli M, Rieke D, Endhardt K, Fang P, Brägelmann J, DeBoer R, El-Dinali M, Aktolga S, Lei Z, Tan P, Rozen SG, Salgia R, Weichselbaum RR, Lingen MW, Story MD, Ang KK, Cohen EE, White KP, Vokes EE, Seiwert TY.

Clin Cancer Res. 2015 Feb 15;21(4):870-81. doi: 10.1158/1078-0432.CCR-14-2481. Epub 2014 Dec 9.

12.

Surgical resection margins in desmoid-type fibromatosis: a critical reassessment.

Cates JM, Stricker TP.

Am J Surg Pathol. 2014 Dec;38(12):1707-14. doi: 10.1097/PAS.0000000000000276.

PMID:
25392923
13.

Detection of internal exon deletion with exon Del.

Guo Y, Zhao S, Lehmann BD, Sheng Q, Shaver TM, Stricker TP, Pietenpol JA, Shyr Y.

BMC Bioinformatics. 2014 Oct 16;15:332. doi: 10.1186/1471-2105-15-332.

14.

Desmoid-type fibromatosis-associated Gardner fibromas: prevalence and impact on local recurrence.

Cates JM, Stricker TP, Sturgeon D, Coffin CM.

Cancer Lett. 2014 Oct 28;353(2):176-81. doi: 10.1016/j.canlet.2014.07.020. Epub 2014 Jul 23.

PMID:
25064609
15.

Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounter™ system.

Stricker TP, Morales La Madrid A, Chlenski A, Guerrero L, Salwen HR, Gosiengfiao Y, Perlman EJ, Furman W, Bahrami A, Shohet JM, Zage PE, Hicks MJ, Shimada H, Suganuma R, Park JR, So S, London WB, Pytel P, Maclean KH, Cohn SL.

Mol Oncol. 2014 May;8(3):669-78. doi: 10.1016/j.molonc.2014.01.010. Epub 2014 Jan 31.

16.

SMARCB1 expression in epithelioid sarcoma is regulated by miR-206, miR-381, and miR-671-5p on Both mRNA and protein levels.

Papp G, Krausz T, Stricker TP, Szendrői M, Sápi Z.

Genes Chromosomes Cancer. 2014 Feb;53(2):168-76. doi: 10.1002/gcc.22128. Epub 2013 Nov 5.

PMID:
24327545
17.

The genomic map of breast cancer: which roads lead to better targeted therapies?

Balko JM, Stricker TP, Arteaga CL.

Breast Cancer Res. 2013;15(4):209. Review.

18.
19.

SMARCB1 protein and mRNA loss is not caused by promoter and histone hypermethylation in epithelioid sarcoma.

Papp G, Changchien YC, Péterfia B, Pecsenka L, Krausz T, Stricker TP, Khoor A, Donner L, Sápi Z.

Mod Pathol. 2013 Mar;26(3):393-403. doi: 10.1038/modpathol.2012.190. Epub 2012 Nov 23.

20.

Negative regulation of activated alpha-2 integrins during thrombopoiesis.

Zou Z, Schmaier AA, Cheng L, Mericko P, Dickeson SK, Stricker TP, Santoro SA, Kahn ML.

Blood. 2009 Jun 18;113(25):6428-39. doi: 10.1182/blood-2008-08-175356. Epub 2009 Mar 3.

21.

Novel collectin/C1q receptor mediates mast cell activation and innate immunity.

Edelson BT, Stricker TP, Li Z, Dickeson SK, Shepherd VL, Santoro SA, Zutter MM.

Blood. 2006 Jan 1;107(1):143-50. Epub 2005 Sep 15.

22.

Pro-collagenase-1 (matrix metalloproteinase-1) binds the alpha(2)beta(1) integrin upon release from keratinocytes migrating on type I collagen.

Dumin JA, Dickeson SK, Stricker TP, Bhattacharyya-Pakrasi M, Roby JD, Santoro SA, Parks WC.

J Biol Chem. 2001 Aug 3;276(31):29368-74. Epub 2001 May 18.

23.

Structural analysis of the alpha(2) integrin I domain/procollagenase-1 (matrix metalloproteinase-1) interaction.

Stricker TP, Dumin JA, Dickeson SK, Chung L, Nagase H, Parks WC, Santoro SA.

J Biol Chem. 2001 Aug 3;276(31):29375-81. Epub 2001 May 18.

24.

Fluorescent detection of Zn(2+)-rich vesicles with Zinquin: mechanism of action in lipid environments.

Snitsarev V, Budde T, Stricker TP, Cox JM, Krupa DJ, Geng L, Kay AR.

Biophys J. 2001 Mar;80(3):1538-46.

25.

Imaging synaptic activity in intact brain and slices with FM1-43 in C. elegans, lamprey, and rat.

Kay AR, Alfonso A, Alford S, Cline HT, Holgado AM, Sakmann B, Snitsarev VA, Stricker TP, Takahashi M, Wu LG.

Neuron. 1999 Dec;24(4):809-17.

Supplemental Content

Loading ...
Support Center